| advanced breast cancer (metastatic) | versus endocrine therapy alone No demonstrated result for efficacy | 1 trial | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| HORIZON, 2013 | temsirolimus + letrozole vs letrozole alone | | | OS 0.89 [0.65; 1.22] PFS 0.90 [0.76; 1.07] |
| Trial | Treatments | Patients | Method |
|---|
| HORIZON, 2013 | oral letrozole 2.5 mg daily/temsirolimus 30 mg daily (5 days every 2 weeks) (n=556) vs. letrozole/placebo (n=556) | first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer | double-blind Parallel groups Sample size: 556/556 Primary endpoint: PFS FU duration: |
|
| renal-cell carcinoma (advanced) | versus No demonstrated result for efficacy temsirolimus inferior to sorafenib in terms of OS in INTORSECT, 2014 | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| ARCC (Hudes) temsirolimus alone, 2007 | temsirolimus vs interferon alpha | OS 0.73 [0.58; 0.92] | | | | INTORSECT, 2014 | temsirolimus vs sorafenib | | OS 1.31 [1.05; 1.63] | PFS 0.87 [0.71; 1.07] |
| Trial | Treatments | Patients | Method |
|---|
| ARCC (Hudes) temsirolimus alone, 2007 | 25 mg of intravenoustemsirolimus weekly (n=209) vs. 3 million U of interferon alfa (with an increase to 18 millionU) subcutaneously three times weekly (n=207) 3 arms: Temsirolimus alone, Temsirolimus plus interferon and interferon alone | patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma | Sample size: 209/207 Primary endpoint: OS FU duration: | | INTORSECT, 2014 | temsirolimus 25 mg once weekly by intravenous (IV) infusion (n=259) vs. sorafenib 400 mg PO twice daily (n=253) | Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib | Sample size: 259/253 Primary endpoint: PFS FU duration: |
|
